The immunomodulatory drug FTY720 is phosphorylated in vivo, and the resulting FTY720 phosphate as a ligand for sphingosine-1-phosphate receptors is responsible for the unique biological effects of the compound. So far, phosphorylation of FTY720 by murine sphingosine kinase (SPHK) 1a had been documented. We found that, while FTY720 is also phosphorylated by human SPHK1, the human type 2 isoform phosphorylates the drug 30-fold more efficiently, due to a lower K m of FTY720 for SPHK2; likewise, murine SPHK2 was more efficient than SPHK1a. Among splice variants of the human SPHKs, an N-terminally extended SPHK2 isoform was even more active than SPHK2 itself. Further SPHK superfamily members, namely ceramide kinase and a "SPHK-like" protein, failed to phosphorylate sphingosine and FTY720. Thus, only SPHK1 and 2 appear to be capable of phosphorylating FTY720. Using selective assay conditions, SPHK1 and 2 activities in murine tissues were measured. While activity of SPHK2 towards sphingosine was generally lower than of SPHK1, FTY720 phosphorylation was higher under conditions favoring SPHK2. In human endothelial cells, while activity of SPHK1 towards sphingosine was two-fold higher than of SPHK2, FTY720 phosphorylation was 7-fold faster under SPHK2 assay conditions. Finally, FTY720 was poorly phosphorylated in human blood as compared to rodent blood, in line with the low activity of SPHK1 and in particular of SPHK2 in human blood. To conclude, both SPHK1 and 2 are capable of phosphorylating FTY720, but SPHK2 is quantitatively more important than SPHK1.
INTRODUCTION
FTY720 is an immunomodulatory drug, which is highly efficacious in models of transplantation and of autoimmune diseases (1) . It was recently found to be effective in kidney transplantation in humans (2) . FTY720 elicits a lymphopenia resulting from the reversible redistribution of lymphocytes from the circulation to secondary lymphoid organs, without leading to general immunosuppression (3, 4) . Conversion of FTY720 to its monophosphate appears to be essential for the effects of the drug on lymphocyte homing, since FTY720 phosphate acts as an agonist at four of the five G-protein-coupled receptors for sphingosine-1-phosphate (S1P) 1 (5, 6) ; it is assumed that at least one S1P receptor is critical to the lymphopenic response induced by FTY720 treatment (2) . More recently, FTY720 was found to stimulate multidrug transporterdependent T-cell chemotaxis to lymph nodes (7) ; in this instance, FTY720 phosphate as the active metabolite is hypothesized to be responsible for stimulation of efflux activity of the lipid transporter Abcb1.
FTY720 has been reported to be phosphorylated ex vivo by rodent lymphoid tissues (5) and whole blood of several species (6) , and is rapidly phosphorylated in vivo (5, 6) . After oral application of FTY720 to rats, the blood levels of the monophosphate exceeded those of the 1 The abbreviations used are: AAL, 2-amino-4-(4-heptyloxyphenyl)-2-methylbutan-1-ol; BSA, bovine serum albumin; CERK, ceramide kinase; DGK, diacylglycerol kinase; FCS, fetal calf serum; GFP, green-fluorescent protein; huSPHK, human sphingosine kinase; HUVEC, human umbelical vein endothelial cells; muSPHK, murine sphingosine kinase; PBS, phosphate-buffered saline; RACE, rapid amplification of cDNA ends; RefSeq, NCBI Reference Sequence Project; S1P, sphingosine-1-phosphate; SPHK, sphingosine kinase; TLC, thin-layer chromatography.
by guest on August 17, 2017 http://www.jbc.org/ Downloaded from parent compound 2-4 fold (5). FTY720 was shown to be a substrate for recombinant murine sphingosine kinase 1a (muSPHK1a) (5) . Studies with chiral analogs of FTY720 (namely the Rand S-enantiomers of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutan-1-ol (AAL) (5)) showed (i) that muSPHK1a catalyzed phosphorylation of AAL(R) but not AAL(S), (ii) that phosphorylation of AAL(R) was essential for binding at S1P receptors in vitro, and (iii) that only AAL(R), as the isomer which gets phosphorylated, was therapeutically effective in experimental autoimmune encephalomyelitis in rats (5) . It was concluded that phosphorylation of FTY720 by SPHK type 1 is essential for its biological activity.
More recently, a second SPHK isoform has been identified and the mouse and human type 2 enzymes have been cloned (8) ; human SPHK (huSPHK) type 2 shares conserved domains with huSPHK1 (about 80 % similarity) but carries additional amino acids in the center and at the Nterminus, making it a larger protein (383 versus 618 amino acids for huSPHK1 and 2, respectively). Distinct kinetic differences have been described for the two enzymes (8) .
Expression of SPHK1 was reported to be highest in lung and spleen, and of SPHK2 in liver and heart (8, 9) . SPHKs have received considerable interest because their natural reaction product S1P
has been recognized as a signalling molecule with both intra-and extracellular actions (recently reviewed in (10,11)). Presently, a clear-cut functional difference between the two enzymes SPHK1 and 2 has not been described, and most studies so far measured total SPHK activity increases upon stimulation of cells; only recently, selective antisense DNA and siRNA tools have been utilized (12, 13) .
Here we studied the phosphorylation of FTY720 by recombinant SPHK1 and 2 in vitro and by the endogeneous enzymes in murine tissues and in human endothelial cells. We conclude that, while both enzymes are contributing to FTY720 phosphorylation in vivo, SPHK2 is 5 quantitatively the more important enzyme in producing the active form FTY720 phosphate.
Furthermore, we determined the tissue distribution of SPHK1 and 2 enzyme activities in the mouse, to supplement previous studies on total SPHK activity in rats (14) .
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In addition, two SPHK1 variants, one 14 and the other 86 amino acid longer at the N-terminus (designated SPHK1+14 and SPHK1+86, accession numbers NP_068807 (in the NCBI Reference Sequence Project database (RefSeq)) and AAH14439 (GenPept), respectively) were retrieved from the IMAGE Consortium Mammalian Gene Collection. They were amplified with Pfu Ultra (Stratagene) using the respective forward primers For expression, constructs were transferred to pcDNA6.2-DEST.
Cloning of murine sphingosine kinases. -MuSPHK1a and 2 were amplified from total RNA of murine lung and from a mouse liver cDNA (Stratagene), respectively. Both PCR products were cloned for expression into pEGFP-C2 as described above for huSPHK1. The amino acid sequence of the insert was identical to the muSPHK1 and 2 protein sequences in SwissProt (O88885 and Q9JIA7, respectively). (9)). Following two freeze/thaw cycles, membranes were centrifuged off (100,000xg, 60 min, 4°C) and the supernatant was harvested. In some instances, pellets were resuspended in lysis buffer for testing. In the case of CERK, the lysis buffer (20 mM MOPS, pH 7.2, 2 mM EGTA, 1 mM dithiothreitol, complete TM protease inhibitors, 10 % glycerol; as described in (5)) was used alternatively.
Protein analysis. Protein concentration in cell lysates were determined using Bradford reagent For some experiments, the buffer was changed either to 50 mM Hepes, pH 7.4, 0.5 % Triton, 15 mM MgCl 2 , 10 % glycerol, 10 mM NaF, 1.5 mM semicarbazide (buffer 1, favouring SPHK1 activity) or 50 mM Hepes, pH 7.4, 15 mM MgCl 2 , 1 M KCl, 10 % glycerol, 10 mM NaF, 1. For whole blood and lymph nodes total RNA was isolated using Trizol reagent according to the protocol of the manufacture (Life Technologies, Paisley, UK). SPHK PCR primers were designed using the GCG Wisconsin Package (Accelrys Inc.). Primers for SPHK1 were designed to detect both SPHK1a and 1b. The primer for β-actin (Actb) was previously described on www.thelabrat.com/protocols. The testing of primer specificity included melting curve analysis and agarose gel electrophoresis of the PCR products. For PCR reaction 5 µl of a 1:10 diluted cDNA sample was subjected to PCR analysis using primer sets (Table 1) Table 1 ). For relative quantification of target gene transcripts normalized to Actb and relative to a calibrator the mathematical model, the "Delta-delta C T method", developed by PE Applied Biosystems (Perkin Elmer, Forster City, CA) was used. Thus, the calibrator (brain is designated as the calibrator in our calculations) has a value of 1, and all other quantities are expressed as an n-fold difference relative to the calibrator.
Analysis of SPHK activity in mouse tissues. -Activity in mouse tissues was determined in analogy to procedures described by Gijsbers et al. (14) . Female Balb/c mice (obtained from
Charles River , Sulzfeld, Germany) were killed and their tissues were quickly dissected; 13 heparinized whole blood was also obtained. The tissues from three animals each were pooled.
Tissues were flushed with ice-cold PBS, weighed, and then homogenized in Potter-Elvejhem homogenisers in 3 volumes of ice-cold tissue lysis buffer (50 mM potassium phosphate buffer, pH 7.4, containing 1 mM EDTA, 1 mM DTT and complete TM protease inhibitors). Samples were centrifuged at 100,000xg at 4°C for 60 min. Supernatants were harvested and the pellet was resuspended in an equal volume of tissue lysis buffer. Samples were subjected to the routine SPHK assay as described above for HEK293 cell lysates, using either buffer 1 or 2. Incubation time was 30 min, which was found to be in the quasi-linear phase of the assay. Activity is reported as mU/g (= nmol of phosphorylated product formation per min per g of tissue).
Assay of endogenous SPHKs activity in HUVEC.
-The activity of SPHK1 and 2 in HUVEC lysates was measured as described for the HEK293 cells, but incubation time was extended to 2 hrs.
Assay of SPHK activity in whole blood. -Heparinized blood was obtained from human donors, Balb/c mice and Wistar rats (Charles River). The blood was diluted with 3 volumes of SPHK cell lysis buffer; following freeze/thawing and centrifugation supernatants were tested in the routine SPHK assay as described above, with sphingosine as the substrate and using either buffer 1 or 2.
Alternatively, the phosphorylation of FTY720 was studied using intact blood cells: heparinized blood was diluted with 3 volumes of RPMI medium containing 10 % FCS and incubated with with low salt and Triton X-100 concentrations, in which both huSPHK1 and 2 are active.
Overexpression of the enzyme activities relative to untransfected cells was about 48-and 127-fold, respectively (mean of three experiments). Based on EGFP fluorescence of the fusion proteins, the amounts of expressed huSPHK1 and 2 were similar within a range of ±7 %; volumes of lysates added per assay were adjusted to allow for equivalent amounts of expressed protein. Figure 1A shows the dependence of reaction rates on sphingosine concentration, and Figure 1B depicts a corresponding Lineweaver-Burk plot. Table 2 gives the observed K m and V max . K m values for sphingosine were equivalent within error limits for huSPHK1 and 2 , while the V max value was 1.5-fold higher for huSPHK1. Since the concentration of huSPHK1 and 2 in the cell lysates (e o ) was equivalent, a comparison of the V max values gives an estimate of the relative catalytic constants (k cat = V max / e o ) of the enzymes. Thus, the catalytic efficiency (k cat /K m ) of huSPHK1 is about 1.3-fold higher than that of huSPHK2 when using sphingosine as substrate.
With FTY720 added to the assays in place of sphingosine, we observed formation of the corresponding monophosphate form, both with huSPHK1 and 2, as confirmed by co-migration with chemically synthesized FTY720 phosphate in two different solvent systems (data not shown). Figure 1C and D show kinetic experiments using FTY720 as substrate. In the case of huSPHK1, saturation of the enzyme with FTY720 could not be reached, due to limited solubility and high K m of the compound. Thus, the K m and V max values given in Table 2 as calculated from by guest on August 17, 2017 http://www.jbc.org/ Downloaded from the available data, can only be rough estimates; the K m value for FTY720 was about 50-fold higher and the V max value 10-fold lower than for sphingosine. In the case of huSPHK2, the K m value for FTY720 was of the same order of magnitude as the value for sphingosine, while V max was 8.3-fold lower (Table 2 ). Comparing the catalytic efficiencies of huSPHK1 and 2 towards FTY720, it can be estimated that huSPHK2 phosphorylates this substrate at least 30-fold more efficiently, mainly due to the lower K m of FTY720 for huSPHK2.
We were interested to find out whether huSPHK2 was also able to phosphorylate the Renantiomer of AAL, a derivative of FTY720 with high biological activity reported to be a substrate for muSPHK1a (5) . Using the recombinant human enzymes in HEK293 cell lysates we showed that the rate of phosphorylation of AAL(R) was 5.4-fold higher with huSPHK2 than with huSPHK1. This is a first example showing that huSPHK2 also has higher activity towards FTY720 derivatives than huSPHK1. The biologically inactive S-enantiomer of AAL was not phosphorylated by either huSPHK1 or huSPHK2.
We also expressed the murine sphingosine kinases (muSPHK) 1a and 2 in HEK293 and determined their kinetic parameters, using both sphingosine and FTY720 as substrate ( Figure   1E ). The K m and V max values are similar to those obtained with huSPHK1 and 2 ( Table 2 ). This might have been predicted based on the high degree of homology between the corresponding human and murine proteins (82 and 86 % for SPHK1 and 2, respectively). Importantly, we again observed preferential phosphorylation of FTY720 by the type 2 isozyme: it can be estimated from the V max /K m values that muSPHK2 phosphorylates this substrate at least 25-fold more efficiently than muSPHK1.
SPHKs in the human genome. -To date, two different human SPHKs (type 1 and 2) encoded on chromosomes 17 and 19, respectively, have been described. We performed a search for splice variants in available sequences of the human genome, and found two variants of the published huSPHK1 protein (AAG01980) (19, 20, 21) , which are longer by 14 or 86 amino acids at the Nterminus (huSPHK1+14 and +86, NP_068807 and AAH14439, respectively). Furthermore, we found one variant of the published huSPHK2 (AAF74124) (8), which is longer by 36 amino acids at the N-terminus (huSPHK1+36; AAH06161).
We expressed these variants in HEK293 cells and measured their activity towards sphingosine and FTY720. As seen from the data in Fig. 1 and Table 2 , the kinetic parameters of all three huSPHK1 variants against both substrates were comparable. While the activity of huSPHK2+36 towards sphingosine was somewhat higher as compared to huSPHK2 (factor of about 1.3), SPHK2+36 featured a significantly higher rate of phosphorylation of FTY720 (factor ~4), due to a higher V max value. Thus, in the case of huSPHK2 the N-terminal extension does influence the catalytic activity of the enzyme, presumably by featuring a conformation which favours substrate turnover.
We searched human protein and predicted protein databases for sequences homologous to the known SPHKs. Among the sequences detected by BLAST, those that contained a diacylglycerol kinase (DGK) catalytic domain (which appears to be essential for catalytic activity of SPHKs (22)) and showed significant homology to all putative family members in a reflexive manner were considered as true relatives. The family members thus defined are: SPHK 1 and 2, ceramide 
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To conclude, it appears that among proteins homologous to SPHKs in the human genome only huSPHK1 and 2 and their splice variants are able to phosphorylate sphingosine and FTY720.
Distribution of SPHK1 and 2 mRNA and activity in mouse tissues. -From the data obtained so far, it became clear that SPHK1 and 2 are the only known enzymes which phosphorylate FTY720
and that recombinant SPHK2 is more efficient in phosphorylating FTY720 than SPHK1. We wanted to extend the latter notion also to endogeneous SPHK activities in vivo, and, therefore, studied the expression and activities of muSPHK1 and 2 in mouse tissues. By quantitative PCR we found that the mRNA for both kinases was present in all tissues investigated. Message levels of muSPHK1 (Fig. 3 A) were highest in lung and spleen, followed by brain, kidney, and lymph nodes, and were lowest in liver (in line with Northern Blot data by Kohama et al. (9)). MuSPHK2 mRNA (Fig. 3 B) was highest in liver, followed by kidney, brain, lung, spleen, and lymph node.
This ranking is in line with Northern blot data by Liu et al. (8).
In order to selectively measure SPHK1 and 2 activities in tissue homogenates, we needed to define buffer conditions where only one or the other enzyme would be active. We exploited the fact that SPHK1 is inhibited by high salt concentration while SPHK2 activity is blocked by high Triton X-100 concentration (8); therefore, the SPHK buffer 1 used here contained 0.5 % Triton X-100 and buffer 2 contained 1 M KCl. The enzyme activity of recombinant huSPHK1 in HEK293 cytosol was blocked by >99 % in buffer 2, while activity of huSPHK2 was inhibited by about 95 % in buffer 1 (see Fig. 3A ). Both enzymes were active in buffer U (used above for the kinetic measurements). Similar results were obtained with the minor fraction of SPHK activities in the pellet of the lysed cells. Furthermore, analogous experiments with muSPHK1 and 2 yielded identical results (data not shown).
We prepared homogenates of ten different mouse tissues, and separated them into a cytosolic and a pellet fraction by ultracentrifugation. Heparinized blood was also obtained and treated like the tissues. In both fractions of tissues and blood we measured activities under the selective buffer conditions for both SPHK1 and 2, using sphingosine or FTY720 as substrates; activities were calculated as formation of phosphorylated product per min and per g of tissue (or blood) ( Table   3 ). When sphingosine was used as substrate, muSPHK1 activity was highest in the spleen, the lung, and the blood (~6-9 mU/g), very low in skeletal muscle and small intestine (~0.05 mU/g), and intermediate in the other tissues (~0.1-0.4 mU/g). The high levels encountered in spleen and lung are in line with the high mRNA for muSPHK1 in these tissues as mentioned above.
Distribution of SPHK1 activity between cytosol and pellet was quite variable: in some instances (liver, blood, brain) the enzyme was almost exclusively found in the cytosol, while in others (especially lymph nodes, Peyer's patches, and spleen) there was a significant association of activity with the insoluble fraction.
SPHK2 activity was lower than SPHK1 activity by factors of 3 to 20 in some tissues, while in brain, liver and lymph nodes SPHK2 activity was similar or somewhat higher than SPHK1 activity. SPHK2 activity was highest in the blood (1.7 mU/g), intermediate in spleen, brain, liver, lung and lymph nodes (0.1-0.65 mU/g), and low but detectable in all other tissues. This is in line with the SPHK2 mRNA levels mentioned above, with the exceptions of liver and blood: liver showed the highest mRNA levels among those tested, but only modest SPHK2 enzyme activity;
blood showed the highest SPHK2 activity, but relatively low mRNA levels. This situation might be due to post-translational regulation of SPHK2 expression and/or activity. SPHK2 activity was predominantely found in the cytosol, with the exception of lymph nodes and Peyer's patches where the enzyme was associated to a significant extent with the membrane fraction.
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FTY720 was phosphorylated more efficiently in the tissue homogenates under conditions favoring SPHK2 activity (factors of 2 to 11 as compared to SPHK1 favoring conditions; Table   3B ), although SPHK2 activity towards sphingosine in most tissues was lower than or similar to SPHK1 activity (see above). SPHK2 activity towards both FTY720 and sphingosine was highest in spleen, brain, lung, lymph nodes, and blood.
In summary, these data demonstrate that both endogeneous SPHK1 and 2 are capable of phosphorylating FTY720 in vivo. Formation of FTY720 phosphate via SPHK2 appears to be quantitatively more important in the organism as a whole despite its generally lower activity levels compared to SPHK1, which is in line with the data on the recombinant enzymes demonstrating more efficient phosphorylation of FTY720 by SPHK2.
A previous study on the tissue distribution of total SPHK activity in the rat (14) found the highest activity in the kidney, also in agreement with data in (24) . Mouse kidney had relatively low SPHK1 and 2 activities in our study, in line with the mRNA levels and also with Northern blot data in (8) and (9) . Based on the data it appears that there are differences in the tissue distribution of SPHKs between species.
Phosphorylation of FTY720 in HUVEC cells. -In order to find out, which of the SPHKs would preferentially phosphorylate FTY720 in human cells, we studied the endogenous activities of HUVECs as a model system. As seen in Fig. 3B , SPHK1 activity towards sphingosine was about 2-fold higher as compared to SPHK2 activity, while FTY720 phosphorylation under SPHK1-favouring conditions was lower by a factor of about 7 compared to SPHK2-favouring conditions.
Thus, in HUVEC FTY720 is phosphorylated by both enzymes, but again SPHK2 is quantitatively more important.
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Phosphorylation of FTY720 in blood of different species. -We compared the rate of phosphorylation of FTY720 in blood of human donors, mice, and rats, by incubating whole blood ex vivo with [ 3 H]-labeled FTY720. Conversion to FTY720 phosphate, the only reaction product observed in the incubations, was significantly more rapid in mouse and rat blood than in human blood ( Figure 3C ). This species difference can most easily be explained by the low SPHK activity, which we measured in human blood as compared to mouse and rat blood ( Figure 3D ). In particular, SPHK2 activity in human blood was very low as compared to rodent blood. Future work will have to address whether there are additional species differences for enzymes dephosphorylating FTY720 phosphate, which could cause different rates of net phosphorylation.
Conclusions. -FTY720 is a highly promising immunomodulating drug, and elucidation of its mode of action is of considerable importance. In this context, a clearer understanding of how and where the active metabolite FTY720 phosphate is formed in the human body is desirable.
Based on our current data we conclude that only two enzymes, SPHK1 and 2, phosphorylate Dsphingosine and FTY720 in vivo, while the two additional proteins detected in the human genome as SPHK-homologues do not act on these substrates. Formally, however, we cannot exclude the existence of homopractic proteins with overlapping function but no detectable homology to SPHKs.
Previous authors have postulated the existence of at least three SPHK isoforms in human platelets (20) (two cytosolic, one membrane form) and in rat tissues (14) (two membrane forms, one cytosolic), based on biochemical criteria (susceptability to detergents, cations, inhibitors).
However, with the availability of recombinant SPHK1 and 2 (8, 9, 19, 21, (23) (24) (25) it has become clear that both enzymes are distributed both to the cytosol (usually the major fraction) and to the membranes. Thus the three forms in ref. 14 and 20 can be explained by the existence of SPHK1 23 and 2, alone. However, as stated above, the existence of additional minor isoforms cannot be totally excluded.
Based on our kinetic studies, SPHK2 is more efficient towards FTY720 than SPHK1. This is reflected by the higher extent of FTY720 phosphorylation in mouse tissues, in human endothelial cells and in human blood when applying assay conditions favouring SPHK2 activity. The observation that SPHK2 is the enzyme predominately responsible for FTY720 phosphate formation in vivo is of high importance for ongoing medicinal chemistry programs on FTY720:
derivatives of FTY720 also need to be converted to the corresponding phosphate before binding to S1P receptors. Thus, understanding of structure-activity-relationship for FTY720 derivatives needs to take into account both their affinities to SPHKs and the affinities of the corresponding phosphates to the S1P receptors. Table 2 . Kinetic parameters of SPHK1 and 2 variants. SPHK-dependent phosphorylation of sphingosine or FTY720 was measured in buffer U at various substrate concentration in cytosol from HEK293 cells transfected with N-terminally EGFP-tagged SPHK1 or 2 expression constructs.
Parameters were calculated from the data depicted in Figure 1 using Table 3 . Distribution of SPHK activity in mouse tissues. Pooled tissues and blood from three Balb/c mice were homogenized and separated into cytosol and pellet fractions by centrifugation. SPHK activities were measured in the fractions, using either sphingosine (A) or FTY720 (B) as substrate, under buffer conditions favoring SPHK1 and 2. Total activity was calculated as the sum of cytosol and pellet contributions.
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